September 2009. Volume 5. Number 3

Prevalence of pneumococcal serotypes and mortality: key to the development of new vaccines 

 
 
 
 
 
 
 
 
 
 
Rating: 0 (0 Votes)
Newsletter Free Subscription
Regularly recieve most recent articles by e-mail
Subscribe
Print
Add to library
Discuss this article

AVC | Critically appraised articles

Harboe ZB, Thomsen RW, Riis A , Valentiner-Branth P, Christensen J J, Lambertsen L , et al. Pneumococcal serotypes and mortality following invasive pneumococcal disease: a population-based cohort study. PLoS Med. 2009;6;e1000081
Reviewers: Rivas Juesas C1, González de Dios J2.
1Servicio de Pediatría. Hospital de Sagunto. Valencia. España.
2Departamento de Pediatría. Hospital General Universitario de Alicante. España.
Correspondence: Cristina Rivas Juesas. Email: crisrijue@hotmail.com
Reception date: 28/07/2009
Acceptance date: 10/08/2009
Publication date: 01/09/2009

Abstract

Author's conclusions: specific serotypes strongly and independently affect invasive peumococcal disease mortality (IPD).

Reviewer's commentary: in accordance with this Danish epidemiological study, the new developing pneumococcal conjugate vaccines will protect against the most common serotypes of IPD in < 5 years (although we do not have evidence enough for the serotypes which produce more deaths), but not in ≥ 5 years, in which they only protect against two of the nine most lethal serotypes (those with adjusted OR> 3 in relation to serotype 1).

How to cite this article

Rivas Juesas C, González de Dios J. Prevalencia y mortalidad de los serotipos de neumococo: elemento clave para el desarrollo de nuevas vacunas. Evid Pediatr. 2009;5:61.

AVC | Critically appraised articles

Harboe ZB, Thomsen RW, Riis A , Valentiner-Branth P, Christensen J J, Lambertsen L , et al. Pneumococcal serotypes and mortality following invasive pneumococcal disease: a population-based cohort study. PLoS Med. 2009;6;e1000081
Reviewers: Rivas Juesas C1, González de Dios J2.
1Servicio de Pediatría. Hospital de Sagunto. Valencia. España.
2Departamento de Pediatría. Hospital General Universitario de Alicante. España.
Correspondence: Cristina Rivas Juesas. Email: crisrijue@hotmail.com
Reception date: 28/07/2009
Acceptance date: 10/08/2009
Publication date: 01/09/2009

How to cite this article

Rivas Juesas C, González de Dios J. Prevalencia y mortalidad de los serotipos de neumococo: elemento clave para el desarrollo de nuevas vacunas. Evid Pediatr. 2009;5:61.

References

  1. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373-83.
  2. Hausdorff WP, Bryant J, Paradiso PR, Siber GR. Wich pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I. Clin Infect Dis. 2000;30:100-21.
  3. Hausdorff WP, Bryant J, Kloek C, Paradiso PR, Siber GR. The contribution of specific pneumococcal serogroups to different disease manifestations: implications for conjugate vaccine formulation and use, part II. Clin Infect Dis. 2000;30:122-40.
  4. San José González MA, Méndez Fernández P. Vacuna conjugada neumocócica heptavalente: ¿luces y sombras? Rev Pediatr Aten Primaria. 2008;10:467-88.
01/09/2009

Linked Comment